Related Experiment Video
Updated: Jun 1, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
[Prognostic analysis of 336 patients with chronic severe hepatitis B]
Jian-Chun Guo1, Chuan-Rong Duan, Yun-Hao Xun
1Hangzhou 6th Hospital, Hangzhou 310014, China. guojianchunl96@126.com
Insights
Antivirus therapy can reduce the death rate in chronic severe hepatitis B (CSHB) patients. Factors like age, prothrombin activity, and complication severity also impact CSHB prognosis.
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Context:
- Chronic severe hepatitis B (CSHB) presents a significant global health challenge.
- Identifying prognostic factors is crucial for managing CSHB patients.
- Retrospective analysis of 336 CSHB patients provides insights into survival outcomes.
Purpose:
- To investigate risk factors influencing the prognosis of chronic severe hepatitis B.
- To identify key indicators for predicting patient outcomes in CSHB.
Summary:
- Age, prothrombin activity (PTA), and the number of complications were significant risk factors for CSHB mortality.
- Antivirus therapy emerged as a significant protective factor, reducing the death rate.
- Sex, family history, and treatments like artificial liver support system (ALSS) or alprostadil did not show significant impact on prognosis.
Impact:
- This study highlights the critical role of antivirus therapy in improving CSHB outcomes.
- Understanding these risk factors can guide clinical decision-making and treatment strategies for CSHB.
- Findings contribute to better patient management and potentially reduced mortality in chronic severe hepatitis B.
Objective:
To investigate the risk factors related to outcome of chronic severe hepatitis B.
Methods:
A total of 336 consecutive patients with chronic severe hepatitis B (CSHB) were analysed retrospectively. According to the outcome, objects were divided into survival group (n = 137) and death group(n = 199), then to observe the differences between them in respect to age, sex, family history, prothrombin activity (PTA), complications including ascites, infection, electrolyte disturbance, upper gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome and the corresponding quantity of complications in each individual, antivirus therapy, artificial liver support system (ALSS) therapy, and alprostadil therapy. Finally, risk factors related to prognosis were selected by stepwise Logistic regression analyse.
Results:
In univariate analyse, significant differences between the two groups were found related to age, PTA, complications and its quantity (P < 0.01 for all), and antivirus therapy (P < 0.05) rather than sex, family history and treatment of ALSS or alprostadil. Logistic regression revealed that risk factors comprised of PTA and quantity of complications, antivirus therapy was the only protective factor.
Conclusion:
A numbers of factors including age, PTA, complications and its quantity, and antivirus therapy affect the prognosis of CSHB, among which, antivirus therapy can reduce the death rate.
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Viral Hepatitis I: Introduction
